Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

PURPOSE: A phase I trial of veliparib in combination with topotecan plus carboplatin (T+C) demonstrated 33% objective response rate in patients with hematological malignancies. The objective is to perform exposure-response analysis to inform the phase II trial design. EXPERIMENTAL DESIGN: Pharmacoki...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Ji, Jiuping, Greer, Jacqueline M., Piekarz, Richard, Karp, Judith E., Pratz, Keith W., Rudek, Michelle A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837045/
https://ncbi.nlm.nih.gov/pubmed/28751440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0143
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares